Sema Mandal
Datos Biográficos
| ID | 7446569 |
|---|---|
| NOMBRE | Sema Mandal |
| NOMBRES | Sema |
| APELLIDO | Mandal |
| FIRMA | MANDAL S |
| AFILIACIONES | Public Health England |
| ORCID | 0000-0003-3379-3118 |
| VERIFICADO | Sí |
| TOTAL DE OBRAS | 9 |
| TOTAL DE CITAS | 0 |
| TOTAL COMO AUTOR | 9 |
| TOTAL COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2012 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2026 |
| ÍNDICE H | 0 |
Can real-world scaling up HCV treatment in people who inject drugs be cost-saving
INTRODUCTION: UK is one of a few countries that are likely to meet WHO HCV elimination targets of reducing incidence to <2 per 100 person years in People Who Inject Drugs (PWID), but the economic case may be important for investment elsewhere and in future in UK. We illustrate the impact of real-world scaled-up HCV treatment to assess under what drug treatment costs could the investment be cost-saving. METHODS: We utilised a mathematical and econ…
Developing a syndromic surveillance tool to support the epidemiological investigation into paediatric acute hepatitis of unknown aetiology in England
We demonstrate how syndromic surveillance provided support to the HUA outbreak using an existing syndromic surveillance framework to develop new indicators based on the newly emerging clinical symptoms. The outputs from the syndromic tool matched clinical and epidemiological findings with respect to trends in other HUA-related data, including clinical and laboratory reports, over time. This work demonstrates the potential for syndromic surveillan…
Understanding hepatitis C virus reinfections in England in the context of eliminating viral hepatitis as a public health concern
HCV reinfection appeared to decrease over the study period, but people were most at risk in the year post-treatment, which remained constant over time. Harm reduction services should be accessible to people who inject drugs and people who have been in prison, particularly soon after treatment
Analysing HCV incidence trends in people who inject drugs using serial behavioural and seroprevalence data
Fractional polynomials provided an adequate fit with relatively few parameters, but splines may be preferable to ensure flexibility, in particular, to detect short-term changes in the rate of first infection over time that may be a result of treatment effects. Although chronic HCV prevalence has declined with treatment scale up over 2016-2020, there is no evidence yet of a corresponding fall in the rate of first infection. Seroprevalence and risk…
Evaluating the effect of direct-acting antiviral agent treatment scale-up on Hepatitis C virus prevalence among people who inject drugs in UK
Real-world evidence showing substantial reductions in chronic HCV associated with increase of HCV treatment scale-up in the community thus supporting the effectiveness of HCV treatment as prevention in people who inject drugs
Results from a retrospective case finding and re-engagement exercise for people previously diagnosed with hepatitis C virus to increase uptake of directly acting antiviral treatment
A substantial number of those included had treatment recorded after the exercise commenced, however, many more remain unengaged. Evaluation of the exercise highlighted areas that could be streamlined to improve future exercises
What do primary care staff know and do about blood borne virus testing and care for migrant patients? A national survey
BBV testing for migrant patients in primary care is usually ad hoc, which is likely to lead to testing opportunities being missed. Knowledge of migrants' entitlements to healthcare varies and could affect access to care. Interventions to improve professional awareness and identification of migrant patients requiring BBV testing are needed to reduce the undiagnosed and untreated burden of BBVs in this vulnerable population
Mapping the hepatitis C cascade of care in people attending drug treatment services in England
Epidemiology of internal contamination with polonium-210 in the London incident, 2006
BACKGROUND: More than 700 UK residents were tested for possible contamination with polonium-210 ((210)Po) following the alleged poisoning of Mr Alexander Litvinenko in London in November 2006. This paper describes the epidemiology of internal contamination with the radionuclide in this group. METHODS: 11 locations in London had been identified as sufficiently environmentally contaminated with (210)Po to present a health risk to people associated …
Sin obras prominentes en esta página.
Epidemiology of internal contamination with polonium-210 in the London incident, 2006
BACKGROUND: More than 700 UK residents were tested for possible contamination with polonium-210 ((210)Po) following the alleged poisoning of Mr Alexander Litvinenko in London in November 2006. This paper describes the epidemiology of internal contamination with the radionuclide in this group. METHODS: 11 locations in London had been identified as sufficiently environmentally contaminated with (210)Po to present a health risk to people associated …
Mapping the hepatitis C cascade of care in people attending drug treatment services in England
What do primary care staff know and do about blood borne virus testing and care for migrant patients? A national survey
BBV testing for migrant patients in primary care is usually ad hoc, which is likely to lead to testing opportunities being missed. Knowledge of migrants' entitlements to healthcare varies and could affect access to care. Interventions to improve professional awareness and identification of migrant patients requiring BBV testing are needed to reduce the undiagnosed and untreated burden of BBVs in this vulnerable population
Results from a retrospective case finding and re-engagement exercise for people previously diagnosed with hepatitis C virus to increase uptake of directly acting antiviral treatment
A substantial number of those included had treatment recorded after the exercise commenced, however, many more remain unengaged. Evaluation of the exercise highlighted areas that could be streamlined to improve future exercises
Developing a syndromic surveillance tool to support the epidemiological investigation into paediatric acute hepatitis of unknown aetiology in England
We demonstrate how syndromic surveillance provided support to the HUA outbreak using an existing syndromic surveillance framework to develop new indicators based on the newly emerging clinical symptoms. The outputs from the syndromic tool matched clinical and epidemiological findings with respect to trends in other HUA-related data, including clinical and laboratory reports, over time. This work demonstrates the potential for syndromic surveillan…
Understanding hepatitis C virus reinfections in England in the context of eliminating viral hepatitis as a public health concern
HCV reinfection appeared to decrease over the study period, but people were most at risk in the year post-treatment, which remained constant over time. Harm reduction services should be accessible to people who inject drugs and people who have been in prison, particularly soon after treatment
Analysing HCV incidence trends in people who inject drugs using serial behavioural and seroprevalence data
Fractional polynomials provided an adequate fit with relatively few parameters, but splines may be preferable to ensure flexibility, in particular, to detect short-term changes in the rate of first infection over time that may be a result of treatment effects. Although chronic HCV prevalence has declined with treatment scale up over 2016-2020, there is no evidence yet of a corresponding fall in the rate of first infection. Seroprevalence and risk…
Evaluating the effect of direct-acting antiviral agent treatment scale-up on Hepatitis C virus prevalence among people who inject drugs in UK
Real-world evidence showing substantial reductions in chronic HCV associated with increase of HCV treatment scale-up in the community thus supporting the effectiveness of HCV treatment as prevention in people who inject drugs
Can real-world scaling up HCV treatment in people who inject drugs be cost-saving
INTRODUCTION: UK is one of a few countries that are likely to meet WHO HCV elimination targets of reducing incidence to <2 per 100 person years in People Who Inject Drugs (PWID), but the economic case may be important for investment elsewhere and in future in UK. We illustrate the impact of real-world scaled-up HCV treatment to assess under what drug treatment costs could the investment be cost-saving. METHODS: We utilised a mathematical and econ…
Medicine (7 obras) · Hepatitis C virus research (6 obras) · Environmental health (5 obras) · Hepatitis B Virus Studies (5 obras) · HIV, Drug Use, Sexual Risk (5 obras) · Public health (5 obras) · Internal Medicine (4 obras) · Biostatistics (3 obras) · Epidemiology (3 obras) · Family medicine (3 obras)